The discovery of BILN 2061 - An orally bioavailable small molecule inhibitor of the HCV serine protease and a promising antiviral for treatment of hepatitis C.

被引：0

作者：

Lamarre, D ^{[1
]}

Bailey, M ^{[1
]}

Bolger, G ^{[1
]}

Cameron, D ^{[1
]}

Cartier, M ^{[1
]}

Faucher, AM ^{[1
]}

Goudreau, N ^{[1
]}

Kukolj, G ^{[1
]}

Lagace, L ^{[1
]}

Pause, A ^{[1
]}

Rancourt, J ^{[1
]}

Thibeault, D ^{[1
]}

Tsantrizos, Y ^{[1
]}

Llinas-Brunet, M ^{[1
]}

机构：

[1] Boehringer Ingelheim Canada Ltd, Res & Dev, Laval, PQ, Canada

来源：

HEPATOLOGY | 2002年 / 36卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

464

引用

页码：279A / 279A

页数：1

共 50 条

[1] BILN 2061 ZW -: an orally bioavailable small molecule inhibitor of the HCV serine protease and a promising antiviral for treatment of hepatitis C
Lamarre, D
Bailey, M
Bolger, G
Cameron, D
Cartier, M
Faucher, AM
Goudreau, N
Kukolj, G
Lagacé, L
Pause, A
Rancourt, J
Thibeault, D
Tsantrizos, Y
Llinàs-Brunet, M
ANTIVIRAL THERAPY, 2002, 7 (04) : L101 - L101
[2] Discovery of BILN 2061 -: A small molecule inhibitor of the hepatitis C virus serine protease.
Llinàs-Brunet, M
Bailey, M
Bolger, G
Cameron, D
Cartier, M
Faucher, AM
Goudreau, N
Kukolj, G
Lagacé, L
Pause, A
Rancourt, J
Thibeault, D
Tsantrizos, Y
Lamarre, D
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U231 - U231
[3] Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
Hinrichsen, H
Benhamou, Y
Wedemeyer, H
Reiser, M
Sentjens, RE
Calleja, JL
Forns, X
Erhardt, A
Crönlein, J
Chaves, RL
Yong, CL
Nehmiz, G
Steinmann, GG
GASTROENTEROLOGY, 2004, 127 (05) : 1347 - 1355
[4] Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061
Herrmann, Eva
Zeuzem, Stefan
Sarrazin, Christoph
Hinrichsen, Holger
Benhamou, Yves
Manns, Michael P.
Reiser, Markus
Reesink, Henk
Calleja, Jose L.
Forns, Xavier
Steinmann, Gerhard G.
Nehmiz, Gerhard
ANTIVIRAL THERAPY, 2006, 11 (03) : 371 - 376
[5] Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype
Reiser, M
Benhamou, Y
Sentjens, R
Wedemeyer, H
Calleja, L
Forns, X
Croenlein, J
Yong, C
Nehmiz, G
Steinmann, G
HEPATOLOGY, 2003, 38 (04) : 221A - 221A
[6] Hepatitis C viral kinetics in chronically infected patients treated with the serine protease inhibitor BILN 2061
Herrmann, E
Zeuzem, S
Sarrazin, C
Hinrichsen, H
Benhamou, Y
Wedemeyer, H
Steinmann, G
Nehmiz, G
JOURNAL OF HEPATOLOGY, 2004, 40 : 24 - 25
[7] Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C
Reiser, M
Hinrichsen, H
Benhamou, Y
Reesink, HW
Wedemeyer, H
Avendano, C
Riba, N
Yong, CL
Nehmiz, G
Steinmann, GG
HEPATOLOGY, 2005, 41 (04) : 832 - 835
[8] Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis.
Wedemeyer, H
Erhardt, A
Schmiegel, W
Hinrichsen, H
Chaves, R
Yong, CL
Nehmiz, G
Steinmann, G
HEPATOLOGY, 2003, 38 (04) : 297A - 297A
[9] Mechanism of drug resistance in hepatitis C: The case of protease inhibitor BILN-2061
Courcambeck, J
Perbost, R
Chabaud, P
Pepe, G
Bouzidi, M
Mabrouk, K
Sabatier, JM
Halfon, P
Jouirou, B
JOURNAL OF HEPATOLOGY, 2005, 42 : 104 - 105
[10] Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C genotype 1, with advanced liver fibrosis.
Benhamou, Y
Hinrichsen, H
Sentjens, R
Reiser, M
Manns, MP
Forns, X
Avendano, C
Crönlein, J
Nehmiz, G
Steinmann, G
HEPATOLOGY, 2002, 36 (04) : 304A - 304A

← 1 2 3 4 5 →